Market Place
Sourcing Support
Lipella Pharma Publishes Non-Steroid Oral Lichen Planus Treatment
03 Dec 2024 //
GLOBENEWSWIRE
Lipella Completes Ph 2a Trial of LP-310 for Oral Lichen Planus
21 Nov 2024 //
GLOBENEWSWIRE
Lipella Extended Exclusivity Of US Patent for Liposomal Platform
12 Nov 2024 //
GLOBENEWSWIRE
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
01 Nov 2024 //
GLOBENEWSWIRE
Lipella Pharma to Present at Spartan Capital Investor Conference
29 Oct 2024 //
GLOBENEWSWIRE
Lipella Announces US Patent Allowance for Liposomal Drug Delivery
15 Oct 2024 //
GLOBENEWSWIRE
Lipella Pharma to Present at 2024 Maxim Healthcare Virtual Summit
09 Oct 2024 //
GLOBENEWSWIRE
Lipella Pharmaceuticals Reports Early Results for LP-310 Phase 2a
24 Sep 2024 //
GLOBENEWSWIRE
Lipella Pharmaceuticals To Attend H.C. Wainwright Investment Conference
27 Aug 2024 //
GLOBENEWSWIRE
Lipella Pharma Launches Registry For Oral Lichen Planus Research
22 Aug 2024 //
GLOBENEWSWIRE
Lipella Presents Advanced Bladder Imaging Technique At ICICJ
21 Aug 2024 //
GLOBENEWSWIRE
Lipella doses first two patients in phase 2a Oral Lichen Planus clinical trial
13 Aug 2024 //
PHARMABIZ
Lipella Doses First Patients In Oral Lichen Planus Trial
12 Aug 2024 //
GLOBENEWSWIRE
Lipella Pharmaceuticals Announces $1.28M At-Market Registered Direct Offering
01 Aug 2024 //
GLOBENEWSWIRE
Lipella Pharmaceuticals Closes $1.28M Registered Direct Offering
01 Aug 2024 //
GLOBENEWSWIRE
Lipella Initiates Phase 2a Trial For LP-310 In Oral Lichen Planus
29 Jul 2024 //
GLOBENEWSWIRE
Lipella Completes Site Initiation For LP-310 Phase 2a In Oral Lichen
31 May 2024 //
GLOBENEWSWIRE
Lipella Presents Abstract At 2024 ASCO Annual Meeting
29 May 2024 //
GLOBENEWSWIRE
Lipella To Advance Lead To Phase 2b After FDA Guidance
21 May 2024 //
GLOBENEWSWIRE
Lipella Pharmaceuticals Expands Advisory Board with Oncology Experts
17 Apr 2024 //
GLOBENEWSWIRE
Lipella Pharmaceuticals to Publish Abstract at ASCO 2024
05 Apr 2024 //
GLOBENEWSWIRE
Lipella Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
03 Apr 2024 //
GLOBENEWSWIRE
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410
05 Mar 2024 //
GLOBENEWSWIRE
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
20 Feb 2024 //
GLOBENEWSWIRE
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress
20 Dec 2023 //
GLOBENEWSWIRE
FDA Grants Orphan Designation for Lipella`s LP-310 Drug Candidate
10 Nov 2023 //
PR NEWSWIRE
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement
25 Oct 2023 //
PR NEWSWIRE
Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference
23 Oct 2023 //
ACCESSWIRE
Lipella Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus
20 Oct 2023 //
PR NEWSWIRE
Lipella Pharmaceuticals` Phase 2a Clinical Study Results Published
21 Sep 2023 //
PR NEWSWIRE
Lipella Pharmaceuticals Reports 1Q 2023 FYR Results and Corporate Update
15 May 2023 //
PR NEWSWIRE
Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the AUAAM
01 May 2023 //
PR NEWSWIRE
Lipella inks manufacturing collaboration agreement with Cook MyoSite
19 Apr 2023 //
PHARMABIZ
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement
17 Apr 2023 //
PR NEWSWIRE
Lipella Pharmaceuticals, Cook MyoSite Enter Manufacturing Agreement
17 Apr 2023 //
CONTRACT PHARMA
Lipella Pharma Doses First Patient in Human Study of Innovative Contrast Agent
05 Apr 2023 //
PR NEWSWIRE
Lipella Provides Business Update and Reports 2022 Financial Results
31 Mar 2023 //
PR NEWSWIRE
Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial
16 Mar 2023 //
PR NEWSWIRE
Lipella reports results from phase 2a of LP-10 for haemorrhagic cystitisn
13 Jan 2023 //
PHARMABIZ
Lipella rises as Phase II bladder disorder drug shows promise
12 Jan 2023 //
NASDAQ
Lipella to Present at January 2023 Biotech Showcase in San Francisco
09 Jan 2023 //
PR NEWSWIRE
Lipella Announces Closing of Initial Public Offering for Gross Proceeds of $7 M
22 Dec 2022 //
PRNEWSWIRE
